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Abstract
Purpose of review We aim to report on the current status of cardiovascular screening of
athletes worldwide and review the up-to-date evidence for its efficacy in reducing sudden
cardiac death in young athletes.
Recent findings A large proportion of sudden cardiac death in young individuals and
athletes occurs during rest with sudden arrhythmic death syndrome being recognised as
the leading cause. The international recommendations for ECG interpretation have re-
duced the false-positive ECG rate to 3% and reduced the cost of screening by 25% without
compromising the sensitivity to identify serious disease. There are some quality control
issues that have been recently identified including the necessity for further training to
guide physicians involved in screening young athletes.
Summary Improvements in our understanding of young sudden cardiac death and ECG
interpretation guideline modification to further differentiate physiological ECG patterns
from those that may represent underlying disease have significantly improved the efficacy
of screening to levels that may make screening more attractive and feasible to sporting
organisations as a complementary strategy to increased availability of automated external
defibrillators to reduce the overall burden of young sudden cardiac death.
Introduction
The sudden death of a young individual is a tragic and
highly emotional event. Apart from the devastation
within a family unit, the sudden nature of the event
and the loss of decades of life have a lasting impact on
friends, peers, and both the lay and medical communi-
ties. Deaths are usually attributable to hereditary or
congenital abnormalities affecting the cardiac structure
or the electrical system of the heart. Such cases galvanise
discussion between physicians, health authorities and
the lay community with an emphasis on improving
understanding of the conditions predisposing to sudden
cardiac death (SCD) and development of effective pre-
ventative strategies.
Much of the data on SCD in young individuals (aged
under 35 years) is derived from studies of highly trained
young competitive athletes. Deaths in this cohort, whilst
rare, are often high profile and are afforded significant
visibility. Identification of athletes at risk of SCD has be-
come an important focus of the medical community on
the premise that themajority of responsible diseases canbe
detected during life, and acceptable interventions such as
lifestyle, pharmacological therapy, radiofrequency ablation
of accessory pathways or implantation of a cardioverter
defibrillator are available to reduce the risk of SCD.
Pre-participation cardiovascular screening (PPS) of
young athletes has been endorsed by learned scientific
organisations bodies and sporting governing bodies in-
cluding the European Society of Cardiology (ESC), the
American Heart Association (AHA), International Olym-
pic Committee (IOC) and Fédération Internationale de
Football Association (FIFA) [1–4]. However, screening of
athletes is still not universally accepted due to concerns
primarily related to the lack of randomised control evi-
dence for its efficacy, reliability issue and cost. This review
article will aim to address the current status of cardiovas-
cular screening of athletes worldwide and review the up-
to-date evidence for its efficacy in reducing SCD in young
athletes.
Sudden cardiac death in athletes: the magnitude of the problem
There is widespread agreement that SCD is the leading medical cause of
death in athletes [5, 6]. Current estimates of the incidence of SCD in
athletes vary widely from almost one in a million to 1:23,000 athletes
per year, whilst some subpopulations of athletes are reported at even
higher risk with an incidence of 1 in 3000 [5, 7••]. Accurate calculation
of the incidence of SCD in athletes requires a precise numerator (number
of deaths per year) and an exact denominator (number of athlete partic-
ipants per year) in the population studied. Variability in either of these
accounts for unreliable estimates of incidence. It is challenging to compare
studies with heterogeneous case identification methods that originate from
different geographic regions. Passive collection methods using retrospec-
tive review of media reports, electronic databases and insurance claims are
limited by ascertainment and selection bias which underestimate calcula-
tions of incidence. Mandatory reporting systems of athlete’s deaths within
good population demographics offer the most reliable method of case
identification although very few currently exist. Furthermore, the inclusion
of all cardiac events (including survivors of sudden cardiac arrest (SCA))
versus only those resulting in death and the population examined can
impact on the incidence estimate. The increasing number of athletes sur-
viving SCA may provide the misconception of drastically falling rates of
SCD. Primary preventative programs target both SCA and SCD; therefore,
it is prudent to incorporate survivors of SCA in estimates of incidence.
Harmon et al. performed a comprehensive review of studies that have
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examined the incidence of SCD in athletes. The objective of this review
was to assess the methodological strengths and weaknesses used to arrive
at estimates, compare studies with estimates of similar populations and
arrive at an approximation of incidence based on the based available
evidence. The incidence of SCD across all 28 studies varied from 1:3000
to 1:917,000; however, studies with higher methodological quality yielded
a higher estimate of incidence ranging from 1:40,000 to 1:80,000 [7••].
Overall, an incidence of 1:50,000 per year is generally accepted as the
incidence of SCD in young athletes. Whilst this rate is fortunately relatively
low, hereditary and congenital abnormalities of the heart are the leading
causes of non-accidental death in young athletes [5, 6].
Demographics of sudden cardiac death in young athletes
Certain populations of sportspeople also seem to be at greater risk. There is a
significant male predominance in SCD amongst young athletes. Data from the
National Centre for Catastrophic Sports Injury Research in high school and
college athletes reported a 5-fold higher incidence of SCD in male compared to
female athletes [8]. In the Veneto region of Italy, where over 110,000 athletes
were evaluated over a 25-year follow-up period, incidence rates of SCDwere 2.6
per 100,000/year in male athletes and 1.1 per 100,000/year in their female
counterparts [9]. Similarly, in a study of National Collegiate Athletic Associa-
tion (NCAA) athletes, male collegiate athletes were at 3-fold higher risk of SCD
compared to female athletes [5, 10]. Several factors are implicated in this sex
difference including a higher prevalence of premature coronary artery disease in
young male athletes and lower participation rates among female athletes par-
ticularly at the elite level, although this trend is changing.
There is limited reported data on incidence of SCD in young individuals of
African/Afro-Caribbean (black) ethnicity within the general population in spite
of the explosion in the number of athletes of this ethnicity competing at the elite
level over the last three decades. Recent studies of the incidence of SCD inNCAA
athletes reported that the incidence of SCD in black athletes as 5.6/100000 per
year, 3-fold higher compared to white athletes [5, 10]. SCD occurs more
frequently in certain sporting disciplines. In the USA, basketball and American
football have the greatest incidence, whereas in Europe, soccer predominates [9,
10]. However, there is the potential for data bias due to higher participation
rates in these sporting disciplines. Although there is a high proportion of
participation by black athletes in sports such as basketball, there are no notable
differences in rates of SCD between black and white collegiate basketball
players. This suggests there may be an intrinsic element of the sport beyond
the ethnic/racial make-up of the participants that predisposes to SCD. Extrap-
olation of these observations suggests that individuals participating in sports of
high dynamic and low isometric intensity are at higher risk of SCD.
Aetiology of sudden cardiac death in young athletes
Understanding both the aetiology and precipitating factors of SCD is para-
mount when devising preventative strategies such as PPS and widespread
availability of automated external defibrillators (AEDs). SCD in young
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individuals is attributable to hereditary and congenital abnormalities of the
heart (Table 1). Based on several independent international studies, the com-
bined prevalence of these diseases in athletes is estimated at 0.3% [11]. Addi-
tionally, there are several important acquired causes during exercise-related
SCD. Cardiomyopathy is the commonest cause of SCD in young athletes
worldwide [6, 12, 13]. Specifically, HCM is the leading cause of SCD in the
USA, whilst in Italy, arrythmogenic cardiomyopathy (AC) predominates [9].
Regional discrepancies between studies reporting HCM and AC as the
commonest cause of SCDmay be explained by genetic variation, ascertainment
bias of identified cases, and different criteria for pathological diagnosis.
Recent data from the USA, Australasia and the UK suggest that autopsy
negative sudden unexplained death in athletes with presumed SCD may be
more common than previously thought. Data from a specialist cardiology
pathology centre in the UK in 357 athletes has shown that in up to 42% of
cases, the heart is structurally normal, and when the toxicology screen is
negative, these deaths are classified as sudden arrhythmic death syndrome
(SADS) [14]. Such cases are often attributed to primary cardiac ion channel
disorders such as the long QT syndrome (LQTS), Brugada syndrome, catechol-
aminergic polymorphic ventricular tachycardia (CPVT) or the congenital acces-
sory pathways. An accurate diagnosis of SADS is of vital importance when
considering a diagnosis of an inherited ion channelopathy or cardiomyopathy
is made in up to 50% of families later evaluated [15]. The role of molecular
Table 1. Causes of sudden cardiac death (SCD) in young sportspeople
Congenital/genetic pathology
Disease of the myocardium Hypertrophic cardiomyopathy
Arrhythmogenic ventricular cardiomyopathy
Dilated cardiomyopathy
Coronary artery disease/anomalies Congenital coronary artery anomalies
Premature atheromatous coronary artery disease
Cardiac conduction tissue abnormalities Wolff–Parkinson–White syndrome
Right ventricular outflow tachycardia
Valvular heart disease and disorders of the aorta Mitral valve prolapse
Congenital aortic stenosis
Marfan syndrome
Ion channelopathies Congenital long QT syndrome
Catecholaminergic polymorphic ventricular tachycardia
Brugada syndrome
Acquired causes
Infections (myocarditis)
Drugs (cocaine, amphetamine)
Electrolyte disturbances (hypokalemia or hyperkalemia)
Hypothermia
Hyperthermia
Trauma (commotio cordis)
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autopsy has been promoted to help shed light of the aetiology of SCD in such
cases even when autopsy is performed at specialised centers [16].
Outcomes of mandatory screening programs in athletes
The Italian experience
The most persuasive evidence supporting the theory that early identification of
disease through ECG screening saves lives comes a large prospective Italian
study of 42,386 competitive athletes aged 12–35 years with 26-year follow-up
[17]. PPS is mandatory in Italy by law, with standard evaluation comprising of
history, physical examination and resting 12-lead ECG. The study compared the
incidence of SCD in athletes in the pre-screening era (1979–1982) and late
screening eras (2003–2004). Fifty-five cases were identified over the course of
the study. The study demonstrated a reduction in the incidence of SCD from
3.6/100,000 person-years to 0.4/100,000 person-years, representing a 90%
reduction in mortality. The predominant reason for this reduction was a de-
crease in SCD due to cardiomyopathy, particularly AC which was a relatively
novel entity during the pre-screening era.
Israel and the USA
The success of the Italian PPS experience has not been replicated in other
countries, with studies in Israel and the USA demonstrating no significant benefit
from PPS in young athletes. Similar to Italy, a mandatory PPS program by law in
Israel since 1997 requires competitive athletes aged 17–34 years to undergo PPS
inclusive of the 12-lead ECG. As in the Italian study, the impact of screening on
SCD risk has been estimated in an Israeli study comparing the incidence of events
before and after implementation of screening [18]. Case identification was
derived through media searches from 2 national newspapers on a daily basis.
The study reported 24 SCD events with an average annual mortality incidence of
2.54 per 100,000/year in the 12 years prior to the implementation of nationwide
screening and 2.66 per 100,000/year in the 12 years after (p = 0.88), consistent
with screening having no apparent effect on SCD rates.
There have been no national screening programs in the USA similar to Italy
and Israel. However, cardiovascular mortality rates have been estimated in
Minnesota, where athletes are evaluated with history and physical examination
alone [19]. Case identification was based mostly on a retrospective analysis of
data provided by different sources, such as the Minnesota State High School
League, news media information services, and internet search engines. Over a
23-year period, 22 deaths were identified. The investigators reported an inci-
dence of SCD of G 1 per 100,000 years throughout the study.
The studies from Israel and USA suggest that PPS of competitive athletes has
little effect on SCD mortality, thus contradicting the findings from Italy. Critics
of the Italian data often cite that the reduced mortality cannot be equivocally
attributed to ECG screening as the study was an observational cohort based
investigation, and not a randomised controlled trial. However, it would be
impossible to conduct a randomised control trial in Italy as screening of
competitive athletes is mandatory by law. The Italian data is further strength-
ened by the prospective study design and case identification through systematic
mandatory reporting system for juvenile sudden death with autopsies
Curr Treat Options Cardio Med  (2018) 20:85 Page 5 of 14  85 
performed by specialist cardiovascular pathologists, equating to a more reliable
denominator when calculating mortality rates. In Israel and the USA, data
collection was retrospective and collected predominantly from media sources
and catastrophic insurance claims leading to likely underestimate the true
mortality rates in these populations. Moreover, both the Israel and USA studies
estimated the true number of athletes participating in sports each year.
Policy to screen young athletes
The AHA and ESC both advocate PPS of young athletes on ethical, medical and
legal grounds. However, they differ in that the AHA recommends taking a
thoroughmedical and family history along with a physical examination, whereas
the ESC recommends routine addition of a 12-lead ECG in the initial screening
stages [1, 20]. The American model is cheap and pragmatic but has poor sensi-
tivity. In a systematic review/meta-analysis of 15 studies comparing screening
strategies in 47,137 athletes, the sensitivity/specificity of ECG was 94%/93%,
history 20%/94% and physical examination 9%/97% to identify cardiovascular
disease associated with SCD [11]. These findings are not entirely surprising as
most athletes are asymptomatic before SCD, and most diseases implicated in
SCD during sports are not associated with physical signs [21]. A family history is
often absent even in affected athletes, because diseases such as HCM and LQTS
have low event rates; therefore, family members may not have presented with a
sentinel event. In a seminal article, Maron et al. described the demographics of
134 young athletes with SCD [22]. Of 115 young athletes who died suddenly and
who had had a standard pre-participation AHAmedical evaluation, only 4 (3%)
were suspected of having heart disease, and the abnormality responsible for the
death was correctly identified in only 1 athlete (0.9%).
ECG interpretation criteria in athletes
Intensive exercise training results in the development of a constellation of physio-
logical alterations in autonomic tone, cardiac structure and cardiac function which
may be represented by electrical anomalies on the ECG. On occasion, the patterns
of electrical alterations related to athletic conditioning overlap with those observed
in individuals with cardiomyopathy. Misinterpretation of these benign physiolog-
ical ECG changes is not uncommon, particularly when performed by physicians
without expertise in sports cardiology [23]. False-positive ECG findings can result
in unnecessary, costly secondary investigations anddisqualification from sport. The
high false-positive ECG rates and impact on specificity are commonly cited as
major limitations of the ECG as a screening test in young athletes [24].
The past three decades has seen a tremendous rise in black athletes compet-
ing at every level of sport. Data from pre-participation programs have informed
our knowledge particularly of black athletes. It is now well established that as
with white counterparts, black athletes reveal a high prevalence of benign,
exercise-related ECG changes, particularly ST segment elevation, voltage criteria
for LVH and early repolarisation [25–27]. It is also apparent that black athletes
demonstrate a higher prevalence of T-wave inversion which would be deemed
abnormal in white athletes and often associated with primary cardiomyopa-
thies. Specifically, T-wave inversion preceded by J-point elevation and an ST
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segment with a convex morphology in the anterior leads V1-4 (Fig. 1) is present
in nearly 13% of highly trained black athletes and is considered a benign
phenomenon [26].
A lower prevalence of ECG abnormalities has consistently been reported in
adult female athletes compared with male athletes. In an Italian study of an
unselected cohort of 32,652 athletes undergoing PPS, females demonstrated an
abnormal ECG prevalence of 9.6% vs. 12.4% in males (p = 0.0001) [28].
It is now recognised that athletes participating in certain sporting disciplines
involving a greater combination of intensity and duration (i.e. endurance athletes)
may have different frequencies of ECG changes than non-endurance athletes. In a
study of 1007 male and 254 female elite adult athletes undergoing PPS, physio-
logical ECG changes were more common in endurance athletes than non-
endurance athletes (90.8% vs 86.0%, p = 0.04), as were multiple (≥ 2) training-
related changes (78.9% vs 53.5%, p G 0.0001) [29]. ECG changes considered
uncommon or pathological were seen in 18.1% of subjects and were twice as
prevalent in endurance athletes compared with non-endurance athletes (29.9% vs
15.1%, pG 0.0001). RVH and deep right precordial T-wave inversion were three
times as common in endurance athletes and were thought to be as a consequence
of increased structural and/or electrical RV remodeling in this subgroup.
Reservations exist around creating unnecessary anxiety for young athletes and
their families; falsely restricting an athlete from competitive sport can have
significant financial, psychological and social implications. More concerning
however is the potential for erroneous diagnosis resulting in a false reassurance
for athletes harboring cardiovascular disease associated with SCD. To address the
issue of high false-positive ECG rates, the last decade has seen several guidelines
Fig. 1. Electrocardiogram from a Black athlete demonstrating voltage criterion for left ventricular hypertrophy, J-point elevation,
and convex ST segment elevation followed by T-wave inversion in V1 to V4 (circles) [34••].
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for ECG interpretation published to aid the physician in the interpretation of the
athlete’s ECG by differentiating physiological ECG changes from those that may
represent underlying disease. Specifically, the 2010 ESC recommendations, Seat-
tle criteria and refined criteria were developed and sequentially improved speci-
ficity of ECG screening by reducing the false-positive rates from22–25% to 5%by
accounting for ECG changes that are physiological in athletes as well as the
impact of ethnicity on the athlete’s ECG [30–33].
In 2017, the international recommendations were devised by a group of
American and European experts with the overarching aim of unifying the
recommendations for interpretation of the athlete’s ECG [34••]. These recom-
mendations account for adolescent athletes, black ethnicity and some non-
specific electrical anomalies, notably axis deviation and voltage criteria for atrial
enlargement. These criteria (Table 2) have been validated in a single nationwide
study of nearly 5000 young British athletes and have demonstrated further
reduction in the proportion of athletes requiring further investigation to 3%,
rates which are likely to be acceptable to the any screening program [35].
Athlete preference
There is no evidence that PPS deters young athletes from participating in compet-
itive sports. On the contrary, screening to promote safe exercise is likely to raise
Table 2. International consensus standards for electrocardiographic interpretation in athletes
Normal Borderline* Abnormal
QRS voltage consistent for LVH or RVH Left axis deviation T waver inversion
Incomplete RBBB Left atrial enlargement ST segment depression
Early repolarisation/ST segment elevation Right axis deviation Pathologic Q waves
ST segment elevation and TWI V1–V4 in Black athletes Right atrial enlargement Complete LBBB
TWI V1–V3 age G 16 years old Complete RBBB QRS ≥ 140 ms duration
Sinus bradycardia or arrhythmia Epsilon wave
Ectopic atrial or junctional rhythm Prolonged QT interval
1st degree AV block Ventricular pre-excitation
Mobitz type I 2nd degree AV block Brugada Type 1 pattern
Profound sinus bradycardia G 30 bpm
PR interval ≥ 400 ms
Mobitz type II 2nd degree AV block
3rd degree AV block
≥ 2 PVCs
Atrial tachyarrhythmias
Ventricular tachyarrhythmias
AV atrioventricular block, LBBB left bundle branch block, LVH left ventricular hypertrophy, RBBB right bundle branch block, RVH right ventricular
hypertrophy, PVC premature ventricular contraction, TWI T-wave inversion
*Further evaluation if two or more ‘borderline’ ECG findings identified. Further evaluation required in the presence of any ‘abnormal’ ECG finding.
No further evaluation required if ‘normal’ ECG findings are found in asymptomatic athletes that report no family history of inherited cardiac
disease or SCD
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awareness of cardiac disease, promote healthier life habits and achieve the most
important goal of western health care organisations: a reduction in cardiovascular
disease burden. A prospective, non-randomised controlled trial of 952 high school
athletes demonstrated that athletes undergoing ECG screening were likely tomore
likely to be satisfiedwith their screening, feel safe during competition, support that
all athletes should receive cardiac screening and state that the ECG had a positive
impact on their training [36]. Individuals with false-positive screening tests were
not found to report excessive anxiety after screening. Nevertheless, support mech-
anisms to assist athletes diagnosed with serious or potentially lethal cardiac
disease should be considered an important part of PPS pathway.
Cost of ECG screening
A central argument that has prevented the national legislation of ECG screening
in young athletes in most countries relates to the financial implications of the
practice [24]. Consequently, screening of athletes with ECG has largely been
confined to athletes participating under the banner of financially endowed
sporting organisations. The ECG itself is a relatively inexpensive test. Cost-
effectiveness studies from the USA have reported the cost per athlete life saved
to range from $44,000 to $204,000 [37, 38]. The reasons for such variation
relate to inconsistencies in the methodology of the studies including variation
in disease prevalence, variation in positive screening tests and differences in cost
of investigations. The studies published to date are therefore not comparable
and are unlikely to be applicable to many western countries where the cost of
investigations is not as expensive as that in the USA. In a British study of nearly
5000 young athletes from 26 different sporting disciplines, modification of
ECG interpretation criteria with the international recommendations was asso-
ciated with significant reductions in the proportion of secondary investigations
following screening and subsequently has been shown to reduce the cost of
ECG screening by nearly 25% without compromising the ability to identify
serious cardiac disease [35, 39]. These findings will be welcomed by sporting
associations that mandate ECG screening in athletes and may allow less finan-
cially endowed organisations to afford ECG screening.
Limitations of screening
Natural history of the conditions being screened
The understanding of the natural history of the disease is an important feature
for any screening program. In particular, a recognisable latent or early stage of
the disease is essential. Given the heterogeneity of the diseases implicated in
SCD and the low event rates in individuals with disease, it is arguable if their
natural history can be fully appreciated. Commendable efforts have beenmade
to risk stratify individuals identified with cardiac disease who are in the early
stage of disease by virtue of being asymptomatic. For example, validated risk
stratification tools exist to predict the prognosis of individuals diagnosed with
HCM. Risk factors for SCD include unheralded syncope, family history of SCD,
severe LVH (9 30mm), sustained or non-sustained ventricular tachycardia, and
attenuated blood pressure response to exercise [40]. Individuals exhibiting ≥ 1
of these five risk markers should be considered for prophylactic insertion of an
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implantable cardioverter defibrillator (ICD). The more recent risk stratification
model proposed by the ESCHCMoutcome group shows promise; however, the
score was derived from a non-athletic cohort and therefore cannot readily be
extrapolated to highly trained athletes diagnosed with disease [41].
Risk stratification for ion channel diseases implicated in SCD in young individ-
uals may be achieved using the resting 12-lead ECG. A QT interval 9 500 msec or
the presence of the spontaneous type 1 Brugada pattern confer a higher risk of SCD
to asymptomatic individuals diagnosed with LQTS and Brugada syndrome respec-
tively [42]. Invasive electrophysiological evaluation of the asymptomatic individ-
uals with the Wolf–Parkinson–White (WPW) ECG pattern may identify those at
elevated risk for SCD. In particular, young patients with shortest pre-excited R-R
interval (SPERRI) ≤ 250 msec in atrial fibrillation are at increased risk [43].
The majority of conditions implicated in SCD are not curative. Screening for
these conditions has however been endorsed on the basis that there are acceptable
interventions available to reduce the risk of SCD in young athletes identified with
disease. Such interventionsmay include lifestyle changes, pharmacological therapy,
radiofrequency ablation for accessory pathways or implantation of an ICD. Phar-
macological therapy with beta blockers is an effective first-line treatment for LQTS
and CPVT [42]. As with all individuals, an ICD is indicated for athletes considered
to be a high risk of SCD andmay be effective at reducing arrhythmogenic deaths in
athletes harbouring structural or electrical cardiac disease [42, 44, 45].
False negatives
The ECG cannot detect all disorders predisposing to SCD in athletes; for example,
the ECG is normal and therefore unable to identify the majority (9 90%) of
individuals with premature coronary artery disease or congenital coronary anom-
alies [24]. Furthermore, the ECGmay be normal in 5–10% of athletes with HCM
and in 25–30% of genetically affected individuals with LQTS [46, 47]. Similarly,
the resting ECG is usually normal in individuals with CPVT [42].
Variation in ECG interpretation
As with any subjective investigation, the effectiveness of the ECG is dependent
on the individual interpretation of the test. A commonly cited criticism of the
ECG as a screening test relate to the potential for variation in ECG interpretation
especially in inexperienced hands. In a study assessing inter-observer agreement
in ECG interpretation in athletes, cardiologists who do not routinely screen
athletes (inexperienced cardiologists) were at least 40% more likely to catego-
rise ECGs as abnormal compared to experienced cardiologists [23]. Addition-
ally, inter-observer agreement rates for ECG interpretation among inexperi-
enced cardiologists were inferior compared to their experienced counterparts.
Whilst experience is undoubtedly useful, inter-observer agreement even
amongst experienced cardiologists was moderate at best, highlighting the need
for further training, and possibly accreditation to support cardiologists involved
in screening young athletes. Recent small studies have demonstrated significant
improvement in ECG interpretation in athletes following online training
among inexperienced physicians and hold promise for the future [48, 49]. A
study by Drezner et al. reported an overall improvement in the sensitivity of
ECG interpretation from 89 to 94% and specificity from 70 to 91% before and
after training with an online ECG interpretation tool based largely on the 2010
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ESC recommendations [48]. Furthermore, the study reported high rates of
agreement in ECG interpretation between cardiologists and other physicians
(96% and 91%, p = 0.053) after training. Exeter et al. assessed ECG interpreta-
tion in two groups of physicians, one which received training with an online
ECG interpretation tool (intervention group) and the other group who read the
same ECG without the tool (control group) [49]. They demonstrated a reduc-
tion in false-positive ECG’s in the intervention group but no difference in
sensitivity between the two groups.
Conclusions
Prevention of SCD in young athletes remains the priority of the sports medicine
community. With a better understanding of the physiological adaptations in
athletes and the electrical consequences of such alterations, ECG criterion
development to guide physicians has significantly improved the efficacy of
ECG screening to acceptable levels of false-positive rates and high rates of
sensitivity to identify athletes at risk of SCD. There is a compelling argument
that these resources would be better off served in improving facilities, training
and availability for cardiopulmonary resuscitation and AEDs. Although such
practice is associated with a significant improvement in survival, it will generally
capture events occurring in public places and sporting arenas [50–52]. A recent
prospective study of young SCD in children and young adults in Australia and
New Zealand reported that almost 40% cases of SCD occurred during sleep, and
similar findings were also observed in a pathology series of athletic SCD in the
UK [14, 53]. These findings suggest that early identification of individuals at risk
through screening may be an important complementary strategy to reduce the
overall burden of SCD in young athletes.
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